ROCHE-MO18458



A single arm study to assess the efficacy and safety of bevacizumab in combination with irinotecan and infusional 5-fluorouracil/folic acid regimens as first line treatment for patients with metastatic colorectal cancer.
Bevacizumab
MO18458
metastatic colorectal cancer
Phase 4
 
April 2015